Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 8/20 | 0.56 |
| ▸ | NOS1 | P29475 | 7/20 | 0.36 |
| ▸ | PNP | P00491 | 2/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | PAH | P00439 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5250159 | 0.86 | HPRT1 (0.60) | HPRT1NOS1PNP | |
| Adamantane SCHEMBL10430835 | 0.84 | HPRT1 (0.52) | HPRT1NOS1 | |
| SCHEMBL1672306 | 0.84 | HPRT1 (0.41) | HPRT1HSD17B10 | |
| SCHEMBL10917986 | 0.84 | HPRT1 (0.52) | HPRT1NOS1PNPNOS3NOS2 | |
| SCHEMBL9739844 | 0.84 | HPRT1 (0.60) | HPRT1NOS1PNPNOS3NOS2 | |
| SCHEMBL22799106 | 0.83 | HPRT1 (0.57) | HPRT1NOS1PNPUSP2HSD17B10 | |
| SCHEMBL21637016 | 0.82 | HPRT1 (0.57) | HPRT1NOS1PNPNOS3NOS2 | |
| SCHEMBL10919938 | 0.82 | HPRT1 (0.54) | HPRT1NOS1USP2CASP7HSD17B10 | |
| SCHEMBL8529902 | 0.81 | HPRT1 (0.58) | HPRT1NOS1PNPUSP2CASP7 | |
| SCHEMBL10919925 | 0.81 | HPRT1 (0.53) | HPRT1NOS1USP2CASP7HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200292535-A1 | METHOD FOR EVALUATION OF TARGET IN HISTOLOGICAL SAMPLE | DAKO DENMARK A/S (DK) | 2020-09-17 | — | — | US | disclosed |
| US-10648970-B2 | Method for evaluation of target in histological sample | AGILENT TECHNOLOGIES, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| EP-2646795-B1 | METHODS FOR ANALYZING IMAGES OF SPECIMENS PROCESSED BY A PROGRAMMABLE QUANTITATIVE ASSAY | DAKO DENMARK AS (DK) | 2019-02-20 | — | — | EP | disclosed |
| US-10180426-B2 | Quantification of single target molecules in histological samples | DAKO DENMARK A/S (DK) | 2019-01-15 | — | — | US | disclosed |
| EP-3402897-A1 | SUBSTRATES, SYSTEMS, AND METHODS FOR NUCLEIC ACID ARRAY SYNTHESIS | Vibrant Holdings, LLC (US) | 2018-11-21 | — | — | EP | disclosed |
| US-9970874-B2 | Methods and systems for analyzing images of specimens processed by a programmable quantitative assay | DAKO DENMARK A/S (DK) | 2018-05-15 | — | — | US | disclosed |
| US-9958449-B2 | Method for enzyme-mediated signal amplification | DAKO DENMARK A/S (DK) | 2018-05-01 | — | — | US | disclosed |
| EP-2699691-B1 | NEW METHOD FOR ENZYME-MEDIATED SIGNAL AMPLIFICATION | DAKO DENMARK AS (DK) | 2017-10-18 | — | — | EP | disclosed |
| WO-2017117292-A1 | SUBSTRATES, SYSTEMS, AND METHODS FOR NUCLEIC ACID ARRAY SYNTHESIS | VIBRANT HOLDINGS, LLC (US) | 2017-07-06 | — | — | WO | disclosed |
| US-9671400-B2 | Conjugate molecules | DAKO DENMARK A/S (DK) | 2017-06-06 | — | — | US | disclosed |
| CN-1642923-A | Peptide nucleic acid oligomers from 1-benzenesulfonyl-3-amino acid side chain-4-(2-nucleobase(acetyl))-piperazin-2-ones | PANAGENE INC (KR) | 2005-07-20 | — | — | CN | disclosed |
| EP-1470114-A4 | PEPTIDE NUCLEIC ACID OLIGOMERS FROM 1-BENZENESULFONYL-3-AMINO ACID SIDE CHAIN-4-(2-NUCLEOBASE(ACETYL))-PIPERAZIN-2-ONES | PANAGENE INC (KR) | 2005-05-11 | — | — | EP | disclosed |
| US-20050026930-A1 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2005-02-03 | — | — | US | disclosed |
| WO-2005009998-A1 | PNA MONOMER AND PRECURSOR | PANAGENE INC. (US) | 2005-02-03 | — | — | WO | disclosed |
| EP-1501812-A1 | PNA MONOMER AND PRECURSOR | Panagene, Inc. (KR) | 2005-02-02 | — | — | EP | disclosed |
| EP-1470114-A1 | PEPTIDE NUCLEIC ACID OLIGOMERS FROM 1-BENZENESULFONYL-3-AMINO ACID SIDE CHAIN-4-(2-NUCLEOBASE(ACETYL))-PIPERAZIN-2-ONES | Panagene, Inc. (KR) | 2004-10-27 | — | — | EP | disclosed |
| US-20030225252-A1 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2003-12-04 | — | — | US | disclosed |
| WO-2003091231-A1 | PNA MONOMER AND PRECURSOR | PANAGENE, INC. (US) | 2003-11-06 | — | — | WO | disclosed |
| US-20030195332-A1 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2003-10-16 | — | — | US | disclosed |
| WO-2003062212-A1 | PEPTIDE NUCLEIC ACID OLIGOMERS FROM 1-BENZENESULFONYL-3-AMINO ACID SIDE CHAIN-4-(2-NUCLEOBASE(ACETYL))-PIPERAZIN-2-ONES | PANAGENE, INC. (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195332-A1 | PNA monomer and precursor | RNGTT, NGLY1, NCL | HPRT1 432/4885NOS1 72/4885PNP 44/4885 |
| US-20030225252-A1 | PNA monomer and precursor | PNISR, RNGTT, NCL | HPRT1 377/4885NOS1 192/4885PNP 77/4885 |
| US-20050026930-A1 | PNA monomer and precursor | RNGTT, POLL, NSUN3 | HPRT1 565/4885NOS1 271/4885PNP 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.